{"entity":{"id":"immunodominance","kind":"term","name":"Immunodominance","aka":[],"tldr":"Immune responses to a set of possible targets are often uneven. Some epitopes attract a stronger measured response than others in the same setting.","summary":"A primary mouse experiment showed that T-cell populations could compete for access to antigen-bearing presenting cells, changing responses to dominant and subdominant epitopes. That identifies one mechanism of immunodominance in the studied system. It does not supply a universal ranking of human tumor epitopes. The antigen design, presentation context and responding repertoire all need to remain attached to an observation of a dominant response.","asOf":"2026-11-09","links":[{"label":"T cells compete for access to antigen-bearing antigen-presenting cells.","url":"https://doi.org/10.1084/jem.192.8.1105"},{"label":"Kotturi et al., Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance (J Immunol 2008)","url":"https://pubmed.ncbi.nlm.nih.gov/18641351/"},{"label":"Schmidt et al., Immunodominance of HLA-A2-restricted hepatitis C virus-specific CD8+ T cell responses is linked to naive-precursor frequency (J Virol 2011)","url":"https://pubmed.ncbi.nlm.nih.gov/21367907/"},{"label":"Wells et al., Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction (Cell 2020)","url":"https://pubmed.ncbi.nlm.nih.gov/33038342/"}],"tags":[],"related":["epitope","multi-epitope-constructs","tcr-repertoire-clonality"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Immunodominance is a contextual hierarchy of measured responses, distinct from encoded target count and from epitope spreading. Presentation, precursor frequency, repertoire, priming, HLA, delivery, immune history, tissue and time can change the hierarchy. A favourable binding prediction does not establish immunogenicity, and more encoded targets do not guarantee balanced immunity or independent tumour coverage.","Naive precursor frequency is the starting abundance of cells with a relevant specificity. Mouse LCMV and human HLA-A2-restricted HCV experiments linked precursor frequencies to response hierarchies. Binding alone did not strictly predict the hierarchy. These studies provide no universal cancer-vaccine weights, human marker requirement or instruction to remove dominant clones.","Fictional matched IFN-gamma ELISpot means of 45, 11 and 5 spots for A, B and C, minus matched background 5, give 40, 6 and 0 spots per 200,000 plated PBMCs. A dominates that measured response. Protocol replicate and positivity rules classify C as undetectable. Zero adjusted spots do not prove absent tumour display or universal uselessness, nor do three encoded sequences imply three equally effective responses.","A measured hierarchy needs offered targets, compartment, cell denominator, baseline, timing, matched per-target stimulation, background and positive controls. Detection thresholds and in vitro expansion can alter apparent ranking. Peptide response is not evidence of natural tumour display or tumour-cell killing."],"category":"Immunology"},"route":"/terms/immunodominance/","neighbours":{"term":[{"id":"epitope","kind":"term","name":"Epitope","route":"/terms/epitope/"},{"id":"epitope-spreading","kind":"term","name":"Epitope spreading","route":"/terms/epitope-spreading/"},{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"},{"id":"multi-epitope-constructs","kind":"term","name":"Multi-epitope constructs and antigen processing","route":"/terms/multi-epitope-constructs/"},{"id":"tcr-repertoire-clonality","kind":"term","name":"T-cell receptor repertoire diversity and clonality","route":"/terms/tcr-repertoire-clonality/"}]}}